Jerry C.Ling

Partner

San Francisco + 1.415.875.5890 Shanghai + 86.21.2201.8000

Connect:

Share

For more than a decade, Jerry Ling has litigated and arbitrated intellectual property and commercial contract disputes and has led investigations into alleged violations of the FCPA and other anticorruption laws for clients operating in China and the Asia-Pacific region.

Jerry has arbitrated breach of contract claims for a global private equity fund in Hong Kong, defended a major telecom manufacturer against patent infringement lawsuits filed in China, and brought trade secret claims on behalf of a global retailer in simultaneous actions across the Asia-Pacific region. He also handles complex U.S. litigation and recently represented a leading technology company in an antitrust dispute in the United States.

Jerry was previously based in Shanghai for 10 years, where he led numerous investigations involving corruption, intellectual property theft, and conflicts of interest. He recently assisted several U.S.-listed companies in responding to government inquiries into FCPA violations in China and Southeast Asia. He frequently leads compliance risk assessments for multinationals with significant operations throughout Asia-Pacific and provides compliance training for Asia-Pacific and global leadership teams.

Jerry also has extensive experience advising clients on their mergers and acquisitions in Asia, including conducting anticorruption due diligence for acquisitions. Representative matters include advising Cardinal Health in its acquisition of Johnson & Johnson's Cordis business for US$1.9 billion, Procter & Gamble's acquisition of Sara Lee's Ambi Pur business for US$470 million, and Textron's sale of its Fluid & Power product lines for US$645 million.

Experience

  • Life sciences company resolves FCPA issues with DOJ and SECJones Day represented a publicly traded life sciences company in an internal investigation and resulting self-disclosure to the U.S. Department of Justice ("DOJ") and U.S. Securities and Exchange Commission ("SEC") involving alleged Foreign Corrupt Practices Act ("FCPA") violations arising out of the company's China operations.
  • Salvadoran mother and daughter obtain asylum after fleeing gang persecutionJones Day successfully represented clients S.P. and J.C. in obtaining asylum.
  • Hyster-Yale acquires 75% of Zhejiang Maximal Forklift TruckJones Day advised Hyster-Yale Materials Handling, Inc. in its $90 million acquisition of 75% of the outstanding shares of, and a controlling interest in, Zhejiang Maximal Forklift Company Limited from KNSN Pipe and Pile Company Limited.
  • Public company discloses FCPA issues to DOJ and SECJones Day coordinated the internal investigation and resulting self-disclosure to the U.S. Department of Justice ("DOJ") and the U.S. Securities and Exchange Commission ("SEC") for a public company involved in industrial and manufacturing work regarding Foreign Corrupt Practices Act ("FCPA") issues arising out of the company’s China office.
  • Public company seeks counsel on acquisition involving security clearanceJones Day counseled a public non-U.S. company regarding requirements relating to acquiring a U.S. subsidiary that maintains a facility security clearance.
  • Owens Corning acquires Pittsburgh Corning for approximately $560 millionJones Day advised Owens Corning in its approximately $560 million acquisition of Pittsburgh Corning, the world’s leading producer of cellular glass insulation systems for commercial and industrial markets.
  • MPE Partners acquires Bath Authority LLC d.b.a. DreamLineJones Day represented MPE Partners in connection with the acquisition and related financing of Bath Authority LLC d.b.a. DreamLine, a market leading, technology-driven designer, manufacturer, and marketer of premium bath and shower products.
  • ARA Asset Management taken private in $1.28 billion LBO led by Warburg Pincus and AVIC TrustJones Day represented ARA Asset Management Limited ("ARA"), an Asian real estate fund management company listed on the Singapore Stock Exchange, in connection with its $1.28 billion leveraged buyout led by Warburg Pincus and AVIC Trust via a scheme of arrangement in Bermuda.
  • Multinational company reports results of internal investigation of alleged FCPA violations to SEC, which takes no actionOn behalf of a multinational company doing business in oil and gas in the Asia-Pacific, South America, and Mexico, Jones Day conducted an internal investigation into allegations of corrupt payments made to procure business.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • Fortune 500 medical device company conducts mock dawn raidJones Day devised and conducted a mock dawn raid and training at the Brazilian headquarters of a U.S.-based Fortune 500 medical device company.
  • Global automotive parts company successfully defends potential adverse administrative action by federal governmentJones Day represented a leading automotive parts manufacturer in defending against possible potential adverse administrative action by the Department of Defense.
  • Micron Technology announces long-term agreement with Powertech Technology for assembly and packaging services in ChinaMicron Technology, Inc. (Micron) and Powertech Technology Inc. (PTI), a leading supplier of integrated circuit (IC) backend services, have entered into a series of agreements forming the basis of a long-term strategic relationship for assembly and packaging services in Xi'an, China.
  • Wabtec acquires Fandstan for $215 millionJones Day advised Wabtec Corporation in the cash acquisition of Fandstan Electric Group Ltd., a leading rail and industrial equipment manufacturer, for $215 million.
  • Audit committee of energy company involved in internal investigationsJones Day represented the audit committee of an energy company in connection with internal investigations concerning the company’s business transactions, and with respect to related shareholder derivative litigation.
  • Multinational corporation conducts review of anticorruption policies and complianceJones Day is advising a multinational corporation in its review of China operations with respect to compliance with the Foreign Corrupt Practices Act.
  • U.S. multinational life sciences company prepares China distribution strategyJones Day is counseling this U.S. multinational life sciences company regarding packaging and distribution of pharmaceuticals, medical devices and health care products in China, including issues relating to manufacturing, packaging and labeling pharmaceutical products, medical device products and healthcare products in the bonded zones of China, data privacy and encryption issues, transfer and sharing of medical data with parties outside of China, setting up of nuclear pharmacies, laboratory equipment importation, and interplay between pharmaceutical pricing and China's new anti-monopoly regime.
  • Privately-held investment advisor seeks advice on FCPA and China Anti-Bribery Law risks involving potential employment corruptionJones Day is advising a privately-held investment advisor on FCPA and China Anti-Bribery Law risks arising from an investigation by PRC authorities in relation to potential employment corruption by a project manager of a China real estate investment company.
  • Healthcare services company conducts internal investigation of allegations of retaliation against former employee in SEC accounting fraud investigation and obtains declination from OSHAJones Day, on behalf of a healthcare services company, conducted an internal investigation of allegations of retaliation against former employee who alleged he was discharged for cooperating in SEC accounting fraud investigation.
  • Toys"R"Us acquires majority stake in existing retail business operations throughout Southeast Asia and Greater ChinaJones Day advised Toys "R" Us, Inc., the largest global retailer of toys and juvenile products, in connection with the acquisition of a 70% interest in the Asia-based Toys "R" Us business operated by Hong Kong-based conglomerate Li & Fung.
    • View All

    December 2018 Alerts

    DOJ Launches China-Focused Criminal Enforcement Initiative

    January 2016 Commentaries

    FCPA 2015 Year In Review

    September 2015 Commentaries

    U.S. Department of Justice Announces Updated Guidelines on Individual Accountability for Corporate Wrongdoing

    December 2013 Commentaries

    International Investigations Global Anti-Corruption Summary

    May 2013 Commentaries

    CIETAC Rebranding in Shanghai and Shenzhen

    August 2012 Commentaries

    Traps for the Unwary in Disputes Involving China

    January 2010 External Publications

    Uncle Sam is Watching: Vicarious liability in China under the FCPA, BusinessForum China

    Speaking Engagements

    • September 26, 2019
      Chinese Companies and the FCPA: What Type of Case is Likely to be the First U.S. FCPA Investigation of a Chinese Company?
    • May 1, 2019
      Cybersecurity and Privacy Laws in China and Asia
    • May 15, 2018
      Life Science Seminar: Anti-corruption Regulations
    • May 15, 2018
      Life Science Seminar: PRC Privacy, State Secret and Cybersecurity Laws
    • March 30, 2018
      ACFE Spring Conference 2018: Fraud Investigative Training Workshop - Ask the Experts!
    • October 11, 2017
      What to Do When . . . Your Company Confronts Anti-Corruption Issues in China or India: The Increasing Coordination of U.S. and International Law Enforcement
    • October 2016
      Business Beyond Borders: What You Need to know about Anti Bribery and Corruption in Asia-Pacific
    • January 26, 2016
      CLE Academy Shanghai 2016
    • December 9, 2015
      Global Corruption Risks and Best Practices for the Life Sciences Industry
    • September 17, 2015
      Jones Day Life Science Seminar: Off Label Promotion and FCA Claims; Corruption
    • June 8-9, 2015
      SEC Conference 2015: Update on SEC Enforcement Initiatives for Asia Based Companies
    • June 17, 2014
      SEC Conference 2014: An Accounting and Reporting Update for US Listed Companies Panel speaker for Corporate Fraud & Other Litigation Issues in China
    • May 6, 2014
      The Continuing Expansion of Health Care Enforcement by U.S. and International Authorities: Key Developments and Implications for the Future
    • December 19-20, 2013
      SEC Conference 2013: An Accounting & Reporting Update for US Listed Companies: 1) Update on SEC Enforcement Initiatives for Asia-Based Companies 2) Corporate Fraud in China: Designing & Implementing Effective Anti-Corruption Programs 3) Corporate Fraud in China: Foreign Corrupt Practices Act & Chinese Companies
    • December 12, 2013
      Shanghai In-house Counsel Forum: General Counsel Roundtable - Complying with Data Privacy and State Secrets Laws in Cross-Border Investigations and M&A
    • December 4, 2013
      Daimler Construction Compliance Workshop
    • October 25,2013
      Duke Journal of Comparative and International Law Symposium on Investment in Emerging Markets:The Challenges of Infrastructure Development, Assessing and Protecting against Corruption and other Investment Risks
    • August 28, 2013
      FCPA Roundtable
    • May 3, 2013
      Doing Business in China: Understanding Corruption Risks and Compliance Challenges in China
    • April 30, 2013
      Doing Business in China: Understanding Corruption Risks and Compliance Challenges in China
    • 2012年10月25日
      在华投资研讨会：外商对华投资新的挑战和机遇
    • October 25, 2012
      China Inbound Seminar: New Challenges and Opportunities for Foreign Investments in China
    • October 24, 2012
      Outbound Seminar "Managing Legal Risks in Global Expansion of Chinese Companies"
    • 2012年10月23日
      生命科学法律剧
    • October 23, 2012
      Life Science Legal Drama - "Mr. Big in Wonderland"
    • May 5, 2012
      M&A in China: Conducting FCPA Due Diligence and Creating an Effective and Practical Post-Closing Compliance Policy, 2nd CCH In-House Legal Conference
    • April 12, 2012
      Due Diligence & Business Valuation in M&A Deals 2012: Conducting Corruption Due Diligence for M&A Deals in China
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.